Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11079771 | 0.83 | ALDH1A1 (0.54) | ALDH1A1AOC3L3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL342251 | 0.80 | GABBR2 (0.36) | CYP1A2CYP2D6CYP2C19MAPTMEN1 | |
| SCHEMBL6937456 | 0.80 | ALDH1A1 (0.43) | ALDH1A1AOC3L3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL5652935 | 0.78 | ALDH1A1 (0.50) | ALDH1A1AOC3L3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL21465820 | 0.78 | ALDH1A1 (0.50) | ALDH1A1AOC3L3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL636927 | 0.77 | GABBR2 (0.54) | AOC3CYP1A2CYP2D6CYP2C19MEN1 | |
| SCHEMBL342850 | 0.77 | GABBR2 (0.56) | AOC3CYP1A2CYP2D6CYP2C19SLC6A4 | |
| SCHEMBL1886201 | 0.77 | GABBR2 (0.56) | AOC3CYP1A2CYP2D6CYP2C19SLC6A4 | |
| SCHEMBL1884058 | 0.77 | GABBR2 (0.56) | AOC3CYP1A2CYP2D6CYP2C19SLC6A4 | |
| SCHEMBL6937460 | 0.76 | ALDH1A1 (0.45) | ALDH1A1AOC3L3MBTL1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190167632-A1 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | MUELLER WOLFGANG S (US) | 2019-06-06 | — | — | US | claimed |
| US-20190125779-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2019-05-02 | — | — | US | claimed |
| US-10238622-B2 | Methods of treating and preventing/reducing the likelihood of Mesial temporal lobe epilepsy (TLE) | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2019-03-26 | — | — | US | claimed |
| US-20170042929-A9 | Methods of Treating Neurological Diseases | UNIVERSITY OF HOUSTON | 2017-02-16 | — | — | US | claimed |
| WO-2016109624-A1 | PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2016-07-07 | — | — | WO | claimed |
| US-20150051166-A1 | Methods of Treating Neurological Diseases | ZIBURKUS JOKUBAS (US) | 2015-02-19 | — | — | US | claimed |
| WO-2014028883-A1 | METHODS OF TREATING OF NEUROLOGICAL DISEASES | UNIVERSITY OF HOUSTON (US) | 2014-02-20 | — | — | WO | claimed |
| EP-2593104-A2 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | Müller, Prof. Dr., Wolfgang (DE) | 2013-05-22 | — | — | EP | claimed |
| US-20120115919-A1 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-05-10 | — | — | US | claimed |
| WO-2011113904-A1 | MEDICAMENTS FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-09-22 | — | — | WO | claimed |
| EP-2106799-A1 | Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor | OWEN Holding LTD (GB) | 2009-10-07 | — | — | EP | claimed |
| US-20080318908-A1 | USE OF GABA AND GABAB AGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2008-12-25 | — | — | US | claimed |
| US-20060241134-A1 | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility | ALTANA PHARMA GA (DE) | 2006-10-26 | — | — | US | claimed |
| US-20060089335-A1 | Compositions and methods for enhancing cognitive function and synaptic plasticity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-04-27 | — | — | US | claimed |
| EP-1644043-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA Pharma AG (DE) | 2006-04-12 | — | — | EP | claimed |
| WO-2005037215-A2 | COMPOSITIONS AND METHODS FOR ENHANCING COGNITIVE FUNCTION AND SYNAPTIC PLASTICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-04-28 | — | — | WO | claimed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | claimed |
| EP-0936906-B1 | REFLUX INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-10 | — | — | EP | claimed |
| US-20030162754-A1 | Use of GABA and GABAB agonists | TUFTS UNIVERSITY | 2003-08-28 | — | — | US | claimed |
| US-6117908-A | Use of GABAB receptor agonists as reflux inhibitors | ASTRA AKTIEBOLAG (SE) | 2000-09-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089335-A1 | Compositions and methods for enhancing cognitive function and synaptic plasticity | GRIN2B, CACNA1B, GRIN2A | ALDH1A1 4467/4885AOC3 2567/4885L3MBTL1 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.